|
|
|
Devery Howerton, Ph.D. |
|
Chief, Laboratory Practice Evaluation and
Genomics Branch, Division of Public Health Partnerships, |
|
National Center for Health Marketing, CDC |
|
Atlanta, GA |
|
|
|
|
Quality System essentials |
|
Basic components of testing |
|
CLIA-waived testing |
|
Issues to consider in test evaluation |
|
|
|
|
|
|
|
|
…provides a basic framework for laboratories and
other healthcare units to direct and control activities and functions along
the path of workflow with a focus on managing quality… |
|
|
|
|
|
|
|
|
|
|
Documents and records |
|
Organization |
|
Personnel* |
|
Equipment |
|
Purchasing and inventory* |
|
Process control* |
|
Information management* |
|
Occurrence management* |
|
Internal and external assessment |
|
Process improvement |
|
Customer service/satisfaction |
|
Facilities and safety* |
|
|
|
|
Apply no matter where a test is done: |
|
Person doing the test (tester) |
|
Testing environment |
|
Test materials |
|
|
|
|
|
Ability and willingness to |
|
read instructions |
|
follow instructions |
|
evaluate results and take appropriate action |
|
Awareness of the need to follow instructions
explicitly |
|
|
|
|
Temperature |
|
Humidity |
|
Lighting |
|
Level, stable work surface |
|
|
|
|
Robustness at temperature and humidity extremes |
|
Shelf life |
|
Test instructions |
|
Packaging and configuration |
|
Specimen collection device |
|
|
|
|
|
|
|
Tests that are |
|
Cleared by FDA for home use; |
|
Employ methodologies that are so simple and
accurate as to render the likelihood of erroneous results negligible; or |
|
Pose no reasonable risk of harm to the patient
if the test is performed incorrectly. |
|
|
|
|
|
|
|
|
|
Obtain Certificate of Waiver (CW) |
|
Follow manufacturer instructions |
|
Permit inspections by HHS |
|
|
|
|
|
|
|
|
|
Monitoring |
|
Glucose, glycated hemoglobin, ketone |
|
Cholesterol, HDL, triglycerides |
|
Screening |
|
Fecal occult blood |
|
Urine dipstick chemistries (e.g., microalbumin,
pH, nitrites, billirubin) |
|
Fertility/pregnancy |
|
Substance abuse |
|
|
|
|
|
|
|
CMS surveys 2002-2004 (n=4214): |
|
12% did not have current instructions |
|
21% did not routinely check for changes |
|
RE: following manufacturers’ instructions, sites
did not |
|
perform quality control 21% |
|
adhere to expiration dates 6% |
|
use appropriate specimen 2% |
|
|
|
|
From CDC Laboratory Medicine Sentinel
Monitoring Network studies (1999-2002): |
|
57% followed manufacturers’ instructions (WA,
n=306) |
|
58% used liquid controls (AK, n=211) |
|
68% followed recommended QC (NY, n=607) |
|
|
|
|
|
|
|
|
FDA sales restrictions for rapid HIV testing |
|
CDC QA guidelines for testing with OraQuick
Rapid HIV test |
|
Good laboratory practices (GLP) for waived
testing sites – CLIAC (MMWR 11/05) |
|
CMS GLP guidance document |
|
Professional organizations, e.g., COLA |
|
|
|
|
Instructions and device familiarization |
|
Evaluation materials, test specimens |
|
Specimen collection |
|
Reproducibility |
|
Antibody concentrations near the cutoff |
|
Comparison with existing method or gold standard |
|
Clinical diagnosis |
|
|
|
|
|
|
|
Test kit stability |
|
Variability in reagent lots and source materials |
|
Adequacy of specimen |
|
Test performance (timing, reading) |
|
Analytic sensitivity/specificity |
|
Methods for assuring quality in the absence of
external controls |
|
|
|
|
|
|
|
|
Follow-up action to be taken by tester |
|
Reactive result |
|
Confirmatory testing |
|
Post-test counseling |
|
Accessing care |
|
Non-reactive result |
|
Considerations for retesting |
|
Manufacturer oversight |
|
Adverse event reporting |
|
Production changes |
|
Lot variability |
|
|
|
|
Basic quality systems approach can be applied to
home testing |
|
Quality recommendations and guidance developed
to address gaps in CLIA-waived testing |
|
Recommendations for test evaluation include
evaluation of the total testing process |
|
|
|